Insight

Insights,

| Lindsay Bealor Greenleaf, JD, MBA - Head of Policy, Research, and Analysis

House and Senate Pass the Consolidated Appropriations Act of 2023

Insights,

| Caitlin Sheetz, MPH - Head of SAVEs

ADVI SAVEs Analysis: Trends in New COVID-19 Treatment Add-on Payments (NCTAP) in Medicare Fee-For-Service

Insights,

| Jared Samuels - Manager

“President Biden’s “Executive Order on Lowering Prescription Drug Costs for Americans”

Insights,

| Caitlin Sheetz, MPH - Head of SAVEs

ADVI SAVEs: UPDATE: Medicare Patients Receiving Aducanumab (Aduhelm™)

Insights,

| Lindsay Bealor Greenleaf, JD, MBA - Head of Policy, Research, and Analysis

Congress just passed the Inflation Reduction Act, with prescription drug policies including government price setting, inflationary penalties, Part D benefit redesign, and a $35 insulin copay cap in Medicare.

Insights,

| Brenna Raines, MHA - Vice President

Medicare Patient Demographics at 340B Covered Entities

Insights,

| Lindsay Bealor Greenleaf, JD, MBA - Head of Policy, Research, and Analysis

Analysis of 2021 Part B Drug Discarded Units in Light of Newly Released Guidance in CY 2023 Medicare Physician Fee Schedule Proposed Rule

Insights,

| Michael Kolodziej, MD, FACP - Senior Advisor

Excitement, Anticipation, Questions Await as ASCO 2022 Begins

Insights,

| Michael Kolodziej, MD, FACP - Senior Advisor

ASCO 2022 is Back the Way it Should Be, in Person